<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235156</url>
  </required_header>
  <id_info>
    <org_study_id>TG0823SUL</org_study_id>
    <nct_id>NCT01235156</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions</brief_title>
  <official_title>A Single-dose, Open Labeled, Multicenter Phase IIa Clinical Study on the Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Furui Pharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Furui Pharmaceuticals Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arrhythmia is a common disease that may be caused by various cardiovascular diseases.&#xD;
      According to statistics, 500,000 people die of severe arrhythmia every year in China, In the&#xD;
      United States, approximately 540,000 patients die each year.This study will evaluate the&#xD;
      effectiveness safety of sulcardine sulfate tablets in the patients with premature ventricular&#xD;
      contractions (and non-sustained VT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arrhythmia is a common disease that may be caused by various cardiovascular diseases. The&#xD;
      incident rate of various types of arrhythmias may be as high as 86-100% in patients who&#xD;
      experience acute myocardial infarction within 10 days. Serious arrhythmias can endanger lives&#xD;
      instantly. According to statistics, 500,000 people die of severe arrhythmia every year in&#xD;
      China, which constitutes approximately 50% of the death rate for cardiovascular diseases. In&#xD;
      the United States, among 1,500,000 myocardial infarction patients, approximately 540,000&#xD;
      patients die each year, which is mainly caused by ventricular fibrillation (VF) and sudden&#xD;
      cardiac death (SCD).&#xD;
&#xD;
      Initially at least 24 subjects who meet the inclusion criteria and do not meet the exclusion&#xD;
      criteria will be enrolled into either of two dose levels under a 3:1 randomization&#xD;
      (active:placebo) take sulcardine sulfate tablets.Dose levels may be dropped, an intermediate&#xD;
      dose level added as needed to deemed appropriate following review of safety and tolerability&#xD;
      data at the prior dose level(200mg,400mg). A safety review committee will review data from&#xD;
      all enrolled subjects at the simultaneous completion of Dosing Cohort 1 and 2 prior to&#xD;
      advancement to the final dose level (800mg BID).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Premature Ventricular Contraction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        18-70 year-old patients with premature ventricular contractions or non-sustained&#xD;
        ventricular tachycardia (VT)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70 years old, body weight 45-80kg, and no sex preference.&#xD;
&#xD;
          2. Frequent premature ventricular contraction, the total number of premature ventricular&#xD;
             beats indicated by Holter monitor greater than 3600 over 24 hours, with or without a&#xD;
             short array of non-sustained ventricular tachycardia (more than 3, but fewer than 10&#xD;
             consecutive ventricular beats).&#xD;
&#xD;
          3. Negative pregnancy test result within 24 hours before the first dose for women of&#xD;
             childbearing age. Females subjects of child bearing age must be on effective birth&#xD;
             control (IUD or compliant use of oral contraceptive), have been surgically sterilized&#xD;
             or abstain from sexual intercourse through the active dosing period and for the first&#xD;
             10 days after dosing.&#xD;
&#xD;
          4. Voluntary participation in the study and the ability to complete the screening and&#xD;
             trial procedures, and to remain in the clinical study site throughout dosing period in&#xD;
             accordance with the protocol.&#xD;
&#xD;
          5. Understand and voluntarily sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of Stage III-IV congestive heart failure.&#xD;
&#xD;
          2. Ejection fraction &lt;35% predicted&#xD;
&#xD;
          3. Polymorphic ventricular tachycardia, sustained ventricular tachycardia.&#xD;
&#xD;
          4. Congenital or acquired long QT syndrome, Torsade de Pointes, or an uncorrected&#xD;
             QT-interval of &gt;480 ms; QRS&gt;120 ms.&#xD;
&#xD;
          5. Unstable angina, active myocarditis, rheumatic fever, or bacterial endocarditis,&#xD;
             elevated Troponin T on work-up.&#xD;
&#xD;
          6. Sinus node dysfunction, atrioventricular block above first degree not controlled by&#xD;
             pacemaker.&#xD;
&#xD;
          7. Complete left or right bundle branch block, or intraventricular block.&#xD;
&#xD;
          8. Hypotension, sitting resting blood pressure below 90/55mmHg.&#xD;
&#xD;
          9. Hypertension as defined by SBP&gt; 160mmHg and/or DBP &gt; 95mmHg&#xD;
&#xD;
         10. Sinus bradycardia (average heart rate lower than 50 beats/min).&#xD;
&#xD;
         11. Liver (liver function tests or bilirubin (direct or indirect) &gt;2XULN, history of&#xD;
             cirrhosis or chronic active hepatitis.&#xD;
&#xD;
         12. Kidney dysfunction (plasma creatinine&gt;1.8 and creatinine clearance calculation &lt;30 as&#xD;
             determined by Cockroft-Gault calculation) or electrolyte or acid-base balance&#xD;
             disorders.&#xD;
&#xD;
         13. Taking digitalis, tricyclic antidepressants, Î² blockers, or calcium channel blockers&#xD;
             within 5 half-lives for a given agent.&#xD;
&#xD;
         14. Thyroid dysfunction.&#xD;
&#xD;
         15. Serious respiratory diseases, Wolff-Parkinson-White syndrome; chronic obstructive&#xD;
             pulmonary disease, asthma requiring medication&#xD;
&#xD;
         16. Cyanotic or other uncorrected significant congenital heart disease.&#xD;
&#xD;
         17. History of allergy to sulfonamides.&#xD;
&#xD;
         18. Taking other anti-arrhythmic drugs or medications that affect cardiac&#xD;
             electrophysiology, or stop taking the above mentioned medications less than 5&#xD;
             half-life of the drug ago.&#xD;
&#xD;
         19. History of taking amiodarone within 1 years.&#xD;
&#xD;
         20. Severe neurosis, menopausal syndrome, chest pain caused by cervical spondylosis.&#xD;
&#xD;
         21. Diseases of the hematopoietic system, or mental illness.&#xD;
&#xD;
         22. Current evidence of alcohol abuse or history of illegal drug abuse.&#xD;
&#xD;
         23. Women of childbearing potential who are pregnant or nursing, or women of childbearing&#xD;
             age who are not on effective birth control (IUD or compliant use of oral&#xD;
             contraceptives and who have a positive urine pregnancy test prior to study.&#xD;
&#xD;
         24. Participation in a clinical trial of other drugs within 3 months.&#xD;
&#xD;
         25. Those considered not suitable to be selected by the investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing chao-yang hosipital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gao M Ming, doctor</last_name>
      <phone>8610-010-85231936</phone>
      <email>gaomingming168@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Liu J Mei, doctor</last_name>
      <phone>8610-010-85231936</phone>
      <email>liujiamei2006@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yang Xin Chun, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking university people's hosipital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhang Ping, doctor</last_name>
      <phone>0086-010-88325264</phone>
      <email>zhp1024@263.net</email>
    </contact>
    <contact_backup>
      <last_name>Li Chun, doctor</last_name>
      <phone>0086-010-88325264</phone>
      <email>yxh9956@vip.sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guo Ji Hong, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>November 4, 2010</study_first_submitted>
  <study_first_submitted_qc>November 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2010</study_first_posted>
  <last_update_submitted>November 4, 2010</last_update_submitted>
  <last_update_submitted_qc>November 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>A Single-dose, Open labeled, Multicenter Phase IIa Clinical Study on the Efficacy and Safety of Sulcardine Sulfate Tablets in Patients with Premature Ventricular Contractions</name_title>
    <organization>Jiangsu Furui Pharmaceuticals Co., Ltd</organization>
  </responsible_party>
  <keyword>Premature ventricular contraction</keyword>
  <keyword>Frequent premature ventricular contraction, with or without a short array of non-sustained ventricular tachycardia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

